Peptides in human body fluids closely mirror processes of protein synthesis, processing and degradation. Since peptide levels and composition in the circulation fluctuate in close correlation with specific condition (either physiological or pathological) of an individual, comprehensive peptide analysis may unravel novel disease biomarkers or pave the way to new diagnostic approaches. Discovery of novel peptide biomarkers could facilitate drug development, as peptides can be used to monitor response to drugs, and thus help determine an optimal therapeutic dosage and assess toxic effects. In this review, we will provide a short overview of typical mass spectrometry-based peptidomics workflow, and give the examples from current literature of how peptidomics studies could potentially improve detection and treatment of cancer and neurodegenerative diseases, the latter including Alzheimer’s and Creutzfeldt-Jakob disease.
Financed by the National Centre for Research and Development under grant No. SP/I/1/77065/10 by the strategic scientific research and experimental development program:
SYNAT - “Interdisciplinary System for Interactive Scientific and Scientific-Technical Information”.